407 related articles for article (PubMed ID: 37108109)
1. Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer.
Munkácsy G; Santarpia L; Győrffy B
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108109
[TBL] [Abstract][Full Text] [Related]
2. Targeting molecular cross-talk between tumor cells and tumor associated macrophage as therapeutic strategy in triple negative breast cancer.
Shettigar A; Salunke R; Modi D; Mukherjee N
Int Immunopharmacol; 2023 Jun; 119():110250. PubMed ID: 37163922
[TBL] [Abstract][Full Text] [Related]
3. The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy.
Li R; Cao L
Front Immunol; 2023; 14():1194020. PubMed ID: 37275874
[TBL] [Abstract][Full Text] [Related]
4. Current Advancements of Plant-Derived Agents for Triple-Negative Breast Cancer Therapy through Deregulating Cancer Cell Functions and Reprogramming Tumor Microenvironment.
Wu TN; Chen HM; Shyur LF
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948368
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem cells in TNBC.
Hua Z; White J; Zhou J
Semin Cancer Biol; 2022 Jul; 82():26-34. PubMed ID: 34147641
[TBL] [Abstract][Full Text] [Related]
6. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N
Gene; 2021 Aug; 792():145728. PubMed ID: 34022297
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T cells: Their role in triple-negative breast cancer progression and metastasis.
Malla RR; Vasudevaraju P; Vempati RK; Rakshmitha M; Merchant N; Nagaraju GP
Cancer; 2022 Mar; 128(6):1171-1183. PubMed ID: 34990009
[TBL] [Abstract][Full Text] [Related]
8. Analysis of single-cell RNA-sequencing data identifies a hypoxic tumor subpopulation associated with poor prognosis in triple-negative breast cancer.
Shi Y; Huang X; Du Z; Tan J
Math Biosci Eng; 2022 Apr; 19(6):5793-5812. PubMed ID: 35603379
[TBL] [Abstract][Full Text] [Related]
9. Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach.
Bareche Y; Buisseret L; Gruosso T; Girard E; Venet D; Dupont F; Desmedt C; Larsimont D; Park M; Rothé F; Stagg J; Sotiriou C
J Natl Cancer Inst; 2020 Jul; 112(7):708-719. PubMed ID: 31665482
[TBL] [Abstract][Full Text] [Related]
10. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
Mehlich D; Marusiak AA
Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
[TBL] [Abstract][Full Text] [Related]
11. Triple-negative breast cancer molecular subtyping and treatment progress.
Yin L; Duan JJ; Bian XW; Yu SC
Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
[TBL] [Abstract][Full Text] [Related]
12. Targeting tumor-stromal interactions in triple-negative breast cancer using a human vascularized micro-tumor model.
Hachey SJ; Hatch CJ; Gaebler D; Mocherla A; Nee K; Kessenbrock K; Hughes CCW
Breast Cancer Res; 2024 Jan; 26(1):5. PubMed ID: 38183074
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
14. Single-Cell Transcriptome Analysis Revealed Heterogeneity and Identified Novel Therapeutic Targets for Breast Cancer Subtypes.
Vishnubalaji R; Alajez NM
Cells; 2023 Apr; 12(8):. PubMed ID: 37190091
[TBL] [Abstract][Full Text] [Related]
15. Recent treatment progress of triple negative breast cancer.
Chang-Qing Y; Jie L; Shi-Qi Z; Kun Z; Zi-Qian G; Ran X; Hui-Meng L; Ren-Bin Z; Gang Z; Da-Chuan Y; Chen-Yan Z
Prog Biophys Mol Biol; 2020 Mar; 151():40-53. PubMed ID: 31761352
[TBL] [Abstract][Full Text] [Related]
16. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment.
Zhou L; Yu CW
Pharmacol Res; 2024 Jun; 204():107205. PubMed ID: 38719195
[TBL] [Abstract][Full Text] [Related]
18. Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease.
Qattan A
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255471
[TBL] [Abstract][Full Text] [Related]
19. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
20. Cyclic Multiplexed-Immunofluorescence (cmIF), a Highly Multiplexed Method for Single-Cell Analysis.
Eng J; Thibault G; Luoh SW; Gray JW; Chang YH; Chin K
Methods Mol Biol; 2020; 2055():521-562. PubMed ID: 31502168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
